Regeneron, Mammoth Partner To Pursue Next-Generation CRISPR-Based Gene Editing For Multiple Diseases; Mammoth To Receive $100M Total Upfront Payment And Equity Investment
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals and Mammoth Biosciences have entered into a partnership to develop next-generation CRISPR-based gene editing therapies for multiple diseases. Mammoth will receive a total of $100 million upfront, including a $95 million equity investment from Regeneron, with potential future payments up to $370 million per target, plus royalties on sales.
April 25, 2024 | 11:28 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals invests $95 million in equity and commits up to $370 million in milestone payments plus royalties in a partnership with Mammoth Biosciences for CRISPR-based therapies.
Regeneron's investment and partnership with Mammoth Biosciences signal a strong commitment to advancing CRISPR technology in therapeutic development. The financial terms and potential for future royalties suggest a positive outlook on the collaboration's success, likely leading to investor optimism about Regeneron's innovative pipeline and long-term growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90